Below are the major categories of rheumatology medications by disease and some examples of meds in each category.
Acute Symptom Reduction
- NSAIDs
- Colchicine
- Glucocorticoids
- IL-1 axis inhibitors
- Intra-articular steroids
- Systemic glucocorticoids
Long-Term Treatment
- Gout (urate-lowering therapies)
- Allopurinol
- Febuxostat
- Pegloticase
- Probenecid
- Pseudogout
- Colchicine
- Hydroxychloroquine can be considered
Pharmacotherapy choice is based on organ involvement and severity of disease.
General SLE Meds
- Anifrolumab
- Azathioprine
- Belimumab
- Cyclophosphamide
- Hydroxychloroquine
- Methotrexate
- Mycophenolate
- Rituximab
- NSAIDs: can be used for arthralgias
- Local or systemic glucocorticoids for acute exacerbations
Lupus Nephritis Therapies
- Systemic steroids
- Azathioprine, PO
- Belimumab
- Calcineurin inhibitors:
- Tacrolimus, PO
- Voclosporin, PO
- Cyclophosphamide
- Mycophenolate, PO
- Rituximab
Sun protection is key!
Initial Treatment
- Steroids:
- PO/IV prednisone equivalent to 1-2 mg/kg/day, then slow taper over months
- Consider pulse steroids in severe patients
- IVIG: 1-2 gm/kg/day
Long-Term Immunosuppression per Rheumatology
- Azathioprine
- JAK inhibitors
- Methotrexate
- Mycophenolate
- Rituximab
- Tacrolimus
- Tocilizumab
-
Physical therapy and rehabilitation are key
Short-Term Therapy
Quick onset, unsafe in high doses, long term
- NSAIDs – do not slow/modify disease
- Glucocorticoids
Long-Term Therapy
DMARD = disease-modifying anti-rheumatic drugs (this means these medications help slow/modify the disease progression)
Conventional Disease Modifying (cDMARD)
Small molecules so can be dosed orally (PO)
- Azathioprine: QD or BID PO
- Hydroxychloroquine: QD or BID PO
- Leflunomide: QD PO
- Methotrexate: Weekly PO or SQ
- Sulfasalazine: BID PO
Biologic Disease Modifying (bDMARD)
Large molecules so have to be injections: subcutaneous (SQ) or intravenous (IV) administration
- TNF-alpha inhibitors
- Adalimumab SQ
- Certolizumab pegol SQ
- Etanercept SQ
- Golimumab, SQ or IV
- Infliximab IV
- B-cell targeting medications
- Rituximab, IV
- IL-6 axis inhibitors
- Sarilumab, SQ
- Tocilizumab, SQ or IV
- CTLA4 agonist
- Abatacept, SQ or IV
Targeted Synthetic DMARD (tsDMARD)
Small molecule so oral but unlike the conventional DMARDs, they are targeted to a particular molecule
- JAK inhibitors
Occupational therapy/physical therapy are vital.
Peripheral Arthritis
- NSAIDs
- Oral agents:
- Sulfasalazine
- Methotrexate
- Apremilast, PO – for psoriatic arthritis
- JAK inhibitors
- Biologics:
- TNF-alpha inhibitors:
- Adalimumab SQ
- Certolizumab pegol SQ
- Etanercept SQ (do not use for uveitis or IBD)
- Golimumab SQ
- Infliximab IV
- IL-12 and/or IL-23 inhibitors:
- IL-17 inhibitors:
- TNF-alpha inhibitors:
Axial Arthritis
- NSAIDs first line
- TNF inhibitors
- JAK inhibitors
- IL-17 inhibitors
Physical therapy is important! Collaboration with dermatology, gastroenterology, ophthalmology, etc., are key for spondyloarthritis.
- Skin fibrosis
- Mycophenolate: can slow skin progression
- Methotrexate
- Raynaud’s:
- Calcium channel blockers
- Topical nitroglycerin
- PDE-5 inhibitors
- Prostacyclin analogues
- Endothelin receptor antagonists
- SSRI fluoxetine
- Arthritis:
- DMARDs: hydroxychloroquine, methotrexate
- ILD:
- Mycophenolate: less toxic than cyclophosphamide
- Cyclophosphamide
- Anti-fibrotics
- SRC: ACEi
- pHTN: PDE-5i, endothelin receptor antagonists, prostacycline analogues, etc.
- GERD/dysphagia: H2 blockers, PPI
Collaboration with dermatology, pulmonary, pHTN specialist, gastroenterology, etc. are key for
systemic sclerosis.
ANCA-Associated Vasculitis
- Usually with rheumatology supervision
- Two-part approach: induction and maintenance
Induction
- High doses of steroids with taper
- Cyclophosphamide
- Rituximab
- Methotrexate
- +/- plasma exchange
- Avacopan as add-on therapy for those with severe active disease
Maintenance Choices
- Azathioprine
- Methotrexate (works well for sinonasal/upper airway disease)
- Rituximab
Additional therapy - PJP prophylaxis: trimethoprim-sulfamethoxazole, dapsone, etc.
- Vit D, calcium
Giant Cell Arteritis
- Systemic steroids with glucocorticoids
- IL6 receptor inhibitor with tocilizumab
- Low dose ASA
- IVIG
- Plasmapharesis